Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA" (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is… Read more
Tonix Pharmaceuticals Holding Corp (TNXP) - Total Liabilities
Latest total liabilities as of September 2025: $21.30 Million USD
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has total liabilities worth $21.30 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tonix Pharmaceuticals Holding Corp - Total Liabilities Trend (2008–2024)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tonix Pharmaceuticals Holding Corp Competitors by Total Liabilities
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Modern High Tech Fiber Co
SHE:300876
|
China | CN¥866.11 Million |
|
CoinShares International Limited
OTCQX:CNSRF
|
USA | $5.77 Billion |
|
Shanghai Golden Union Commercial Management Co Ltd
SHG:603682
|
China | CN¥3.88 Billion |
|
Syrah Resources Limited
PINK:SRHYY
|
USA | $533.96 Million |
|
Quanterix Corp
NASDAQ:QTRX
|
USA | $129.61 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Tonix Pharmaceuticals Holding Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tonix Pharmaceuticals Holding Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tonix Pharmaceuticals Holding Corp (2008–2024)
The table below shows the annual total liabilities of Tonix Pharmaceuticals Holding Corp from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $23.33 Million | -52.32% |
| 2023-12-31 | $48.93 Million | +164.38% |
| 2022-12-31 | $18.51 Million | -16.57% |
| 2021-12-31 | $22.18 Million | +110.56% |
| 2020-12-31 | $10.54 Million | +104.92% |
| 2019-12-31 | $5.14 Million | +93.63% |
| 2018-12-31 | $2.65 Million | +24.18% |
| 2017-12-31 | $2.14 Million | -0.51% |
| 2016-12-31 | $2.15 Million | -68.19% |
| 2015-12-31 | $6.76 Million | +95.83% |
| 2014-12-31 | $3.45 Million | +55.13% |
| 2013-12-31 | $2.22 Million | +91.97% |
| 2012-12-31 | $1.16 Million | -59.77% |
| 2011-12-31 | $2.88 Million | +27841.38% |
| 2010-12-31 | $10.30K | +943.02% |
| 2009-12-31 | $988.00 | -67.07% |
| 2008-12-31 | $3.00K | -- |